BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 15923248)

  • 1. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).
    Gappa M; Zachgo W; von Berg A; Kamin W; Stern-Sträter C; Steinkamp G;
    Pediatr Pulmonol; 2009 Nov; 44(11):1132-42. PubMed ID: 19824054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients.
    Adachi M; Aizawa H; Ishihara K; Ohta K; Sano Y; Taniguchi H; Nakashima M
    Respir Med; 2008 Jul; 102(7):1055-64. PubMed ID: 18394875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate.
    Lundbäck B; Rönmark E; Lindberg A; Jonsson AC; Larsson LG; Pétavy F; James M
    Respir Med; 2006 Jan; 100(1):2-10. PubMed ID: 16243498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
    de Blic J; Ogorodova L; Klink R; Sidorenko I; Valiulis A; Hofman J; Bennedbaek O; Anderton S; Attali V; Desfougeres JL; Poterre M
    Pediatr Allergy Immunol; 2009 Dec; 20(8):763-71. PubMed ID: 19239660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
    Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
    Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
    Rojas RA; Paluga I; Goldfrad CH; Duggan MT; Barnes N
    J Asthma; 2007; 44(6):437-41. PubMed ID: 17654129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C; Petroianni A; Ricci A; Allegra L
    Eur Rev Med Pharmacol Sci; 2005; 9(4):209-15. PubMed ID: 16128040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 18. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C; Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Willits LR; Yates JC; Vestbo J
    Eur Respir J; 2009 Sep; 34(3):641-7. PubMed ID: 19443528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.